Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx
This research is being done to try to reduce radiation side effects that happen with the standard radiation methods. Generally surgery, radiation therapy, and sometimes chemotherapy are standard treatment for people with squamous cell carcinoma of the oropharynx.
The study will look at giving a slightly smaller dose of radiation (de-intensification) to see if regularly expected late toxicities (two years after receiving treatment) can be reduced. This study will also try to see if the smaller dose of radiation is equally effective at treating the cancer and to see if it improves quality of life. Along with this radiation treatment plan some participants in this study will have surgery on their tumor and or receive chemotherapy (cisplatin or carboplatin). The possible surgery and or chemotherapy will be up to the participant's doctor.
Study participants will be tested for the Human Papillomavirus (HPV). This tissue test is required for this study. Some studies have suggested that HPV-related cancer is biologically and clinically different as compared to non-HPV-related cancer. Some studies have found that patients with HPV-related oropharynx cancer have a better response to treatment. This test will help researchers learn more about HPV-related cancer.
Squamous Cell Carcinoma of Oropharynx
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Phase II Study on Treatment De-Intensification in Favorable Squamous Cell Carcinoma of the Oropharynx|
- Grade 3+ late toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]To achieve a prevalence of grade 3+ late toxicity at 2 years < 15% while maintaining a locoregional tumor control > 85 + or - 7% at the same time interval.
- Quality of Life [ Time Frame: Pretreatment, 8 weeks, 3 months, then every 3 months fo rthe first 2 years, then every 6 months for years 3-5 ] [ Designated as safety issue: No ]To determine the quality of life of surviving patients
- Adverse events and their cause [ Time Frame: Pretreatment, 3 months, then every 3 months for the first 2 years, then every 6 months for years 3-5 ] [ Designated as safety issue: Yes ]To determine the nature and prevalence of side effects at different time intervals and describe their relationship to pretreatment function and local dose and treated volume.
|Study Start Date:||January 2010|
|Estimated Study Completion Date:||February 2015|
|Estimated Primary Completion Date:||February 2015 (Final data collection date for primary outcome measure)|
Experimental: Dose de-escalating radiation therapy with chemotherapy
This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)Drug: Cisplatin
Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.Drug: Carboplatin
Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
|Contact: Harry Quon, M.D.||firstname.lastname@example.org|
|Contact: Kelly Szajnaemail@example.com|
|United States, Maryland|
|The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||Recruiting|
|Baltimore, Maryland, United States, 21231|
|Principal Investigator: Quon Harry, M.D.|
|Principal Investigator: Arlene Forastiere, M.D.|
|Sub-Investigator: Ralph Tufano, M.D.|
|Sub-Investigator: Christine Gourin, M.D.|
|Sub-Investigator: Jeremy Richmon, M.D.|
|Sub-Investigator: Wayne Koch, M.D.|
|Sub-Investigator: Nafi Aygun, M.D.|
|Sub-Investigator: William Westra, M.D.|
|Sub-Investigator: Heather Starmer, MA, CCC-SLP|
|Sub-Investigator: Kim Webster, MA,MS, CCC-SLP|
|Sub-Investigator: Donna Tippett, MPH,MA,CCC-SLP|
|Sub-Investigator: Todd McNutt, PhD|
|Sub-Investigator: Amanda Blackford, Sc.M.|
|Sub-Investigator: Mary Griffith, RN|
|Sub-Investigator: Shirl DiPasquale, RN|
|Sub-Investigator: Giuseppe Sanguineti, M.D.|
|Sub-Investigator: Nishant Agrawal, M.D.|
|Sub-Investigator: Christine Chung, M.D.|
|Sub-Investigator: Shanthi Marur, M.D.|
|Sub-Investigator: Moody Wharam, M.D.|
|Principal Investigator:||Quon Harry, M.D.||The Johns Hopkins University School of Medicine|
|Principal Investigator:||Arlene Forastiere, M.D.||The Johns Hopkins University School of Medicine|